January 1 – September 30, 2015
The third quarter in figures
· Total net sales amounted to TSEK 995 (818).
· The loss after tax amounted to TSEK 10,260 (7,935).
· The loss per share amounted to SEK 1.24 (1.59).
· The cash flow from current operations was negative in the amount of
TSEK 9,669 (9,578).
The 9-months in figures
· Total net sales amounted to TSEK 2,970 (1,140).
· The loss after tax amounted to TSEK 30,378 (28,499).
· The loss per share amounted to SEK 4.71 (5.72).
· The cash flow from current operations was negative in the amount of
TSEK 32,724 (27,787).
Important events during the quarter
· During the period the high level results from the “Reader-study” in the US
were published. The results from the study show that the addition of Nevisense
significantly improved the ability of US dermatologists to accurately detect
melanoma. The Reader Study is an important requirement of the application
process to the US Food and Drug Administration (FDA). With the results from the
study, SciBase can now finalize and file its PMA application with the FDA.
· Pareto Securities has during the period exercised the possibility to, in
connection with the initial public offering of SciBase Holding AB (publ)
(“SciBase”), carry out stabilization-like transactions. All stabilization-like
transactions were carried out between June 2, 2015 and June 10, 2015 and no
further stabilization-like transactions will be carried out.
Important events after the end of the period
· No significant events after the period have been reported.
Financial overview
Oct 1
2014 -
July Jan 1 Sep 30 Jan 1 -
1 - - Sep 2015 Dec 31
Sep 30
30
THE GROUP 2015 2014 2015 2014 Rolling 2014
-12
Net sales, 995 818 2 970 1 140 3 430 1 600
SEK ths
Gross margin, 17,6% -42,8% -3,8% -33,9% -8,9% -36,0%
%
Equity/Asset 94,2% 84,4% 94,2% 84,4% 94,2% 78,5%
ratio, %
Net 0,06 0,19 0,06 0,19 0,06 0,27
indebtness,
multiple
Cash 147 37 147 37 147 661 27 566
equivalents, 661 176 661 176
SEK ths
Cashflow from -9 -9 -32 -27 -42 014 -37 077
operating 669 578 724 787
activities,
SEK ths
Earnings per -1,24 -1,59 -4,71 -5,72 -6,68 -7,78
share (before
and after
dilution),
SEK*
Shareholder's 18,93 8,61 24,31 8,61 25,78 6,55
equity per
share, SEK*
Average 8 285 4 985 6 451 4 984 6 085 4 984
number of
shares, 000'*
Number of 8 285 4 985 8 285 4 985 8 285 4 985
shares at
closing of
period, 000'*
Average 15 12 14 12 14 12
number of
employees
Definitions and a glossary are provided on page 15.
For further information please contact:
Simon Grant, CEO, tele : 46 72 887 43 99
Michael Colérus, CFO, tele : 46 70 341 34 72
About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm
that has developed a unique point-of-care device for the accurate detection of
malignant melanoma. Its product, Nevisense, helps doctors to detect malignant
melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig
Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden.
Nevisense is based on substantial research and has achieved excellent results in
the largest clinical study ever conducted on the detection of malignant
melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and
is awaiting FDA clearance in the United States. Nevisense is based on a method
called Electrical Impedance Spectroscopy (EIS), which uses the varying
electrical properties of human tissue to categorize cellular structures and
thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”).
Avanza is the certified advisor. Further information is available on
www.scibase.com.
Interim report
| Source: Scibase Holding AB
Pièces jointes
